ArticleFrontiers in immunology2023
Cross-reactive humoral and CD4
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 6 citations in OpenAlex.
- Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults.Frontiers in immunology · 2026Trial
- A Longitudinal Exploratory Study of SARS-CoV-2 Antibody Dynamics in Young Adults in Bogotá: Lessons from Natural Infection and Post-Vaccination Memory.Biomedicines · 2026Article
- Cellular Immune Response Induced by mRNA Vaccines Against SARS-CoV-2.Immunity, inflammation and disease · 2026Review
- Analysis of immune and autophagy-related genes and their regulatory mechanisms in osteoporosis patients post-menopause.Frontiers in endocrinology · 2026Article
- Long-term dynamics of SARS-CoV-2 immunity in a university hospital in Colombia: A cohort study.IJID regions · 2025Article
- The Effect of SARS-CoV-2 Vaccination on HIV Viral Load in Patients Under Bictegravir/Tenofovir Alafenamide/Emtricitabine Therapy: A Retrospective Observational Study.Healthcare (Basel, Switzerland) · 2025Article
- Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.Journal of medical virology · 2025Observational
- Durability of immune responses to SARS-CoV-2 infection and vaccination.Seminars in immunology · 2024Review
- Neutralization of Different Variants of SARS-CoV-2 by a F(ab')2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain.Antibodies (Basel, Switzerland) · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
23 authors at 8 institutions in 2 countries.
Fabiola MartelInstitute of Human Genetics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
Juliana Cuervo-RojasDepartment of Clinical Epidemiology and Biostatistics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
Juana ÁngelInstitute of Human Genetics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
Beatriz ArizaClinical Laboratory Science Research Group, Clinical Laboratory, Hospital Universitario San Ignacio, Bogotá, Colombia.
John Mario GonzálezGroup of Basic Medical Sciences, School of Medicine, Universidad de Los Andes, Bogotá, Colombia.
Carolina Ramírez-SantanaCenter for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario,, Bogotá, Colombia.
Yeny Acosta-AmpudiaCenter for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario,, Bogotá, Colombia.
Luisa Murcia-SorianoHospital Universitario Mayor-Méderi, Universidad El Rosario, Bogotá, Colombia.
Norma MontoyaHead Clinical Laboratory Unit, Clínica del Occidente, Bogotá, Colombia.
Claudia Cecilia Cardozo-RomeroClinical Laboratory Science Research Group, Clinical Laboratory, Hospital Universitario San Ignacio, Bogotá, Colombia.
Sandra Liliana Valderrama-BeltránDivision of Infectious Diseases, Department of Internal Medicine. School of Medicine, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio Infectious Diseases Research Group, Bogotá, Colombia.
Magda CepedaDepartment of Clinical Epidemiology and Biostatistics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
Julio César CastellanosGeneral Direction, Hospital Universitario San Ignacio, Bogotá, Colombia.
Carlos Gómez-RestrepoDepartment of Clinical Epidemiology and Biostatistics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
Federico Perdomo-CelisInstitute of Human Genetics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
Andreu GazquezDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Alexandria DicksonDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, United States.
James D BrienDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, United States.
José MateusCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Alba GrifoniCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Daniela WeiskopfCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Manuel A FrancoInstitute of Human Genetics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
Pontificia Universidad Javeriana · COHospital Universitario San Ignacio · COLa Jolla Institute for Immunology · USSaint Louis University · USUniversidad del Rosario · COUniversidad Autónoma de Occidente · COUniversidad de Los Andes · COUniversity of California San Diego · US
Funding
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4MLarge Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination75N93019C00065 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI MITCHELL, MAYA · 2019 to 2023
$7.3MSARS-CoV-2 correlates of protection in a Latino-origin populationU01CA260541 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI BRIEN, JAMES D, LOPEZ, MARCOS · 2020 to 2024
$3.4MNCI NIH HHS U01 CA260541NIAID NIH HHS 75N93019C00065NIAID NIH HHS 75N93021C00016
Abstract
The SARS CoV-2 antibody and CD4
Indexed as
COVID-19SARS-CoV-2Antibodies, ViralCD4-Positive T-LymphocytesColombiaCOVID-19 VaccinesHumansT-LymphocytesAntibodies, ViralCOVID-19 Vaccinesantibodybreakthrough infectionsCD4+ T cellhybrid immunitynatural infectionSARS-CoV-2vaccinationvariants
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.